Moderna could re-rate toward $210 by the end of 2027 because the market should move ahead of its free cash flow inflection. That assumes free cash flow reaches breakeven by mid-2028, driven by successful commercialization of its personalized mRNA cancer therapy. x.com 

Moderna is worth roughly $190-215 a share on a probability-weighted outcome tree, above the $157 price after its melanoma vaccine readout. Failure implies $75-85, melanoma-only $125-160, positive Phase 3 lung data $250-400, and broad cancer vaccination far more. The market is more skeptical on lung, and that readout decides the trade. With about 50M shares short, a squeeze could hit $400 before a return to a $120-190 range. Most outcomes sit at or below the price, so defined risk is warranted. … Show more

Moderna looks overvalued at about $80B after its melanoma success sparked a retail frenzy. Its upcoming Phase 2 lung cancer and Phase 3 kidney cancer readouts target cold tumors, with much lower odds than melanoma, though success in either would fuel the rally further. January calls cost about 67% of the share price annualized, the most expensive option seen on an already overvalued stock. The retail-driven trend could continue in the short term. x.com 

Moderna could get explosive above $200 as anyone who shorted last week's valuation downgrade has to cover. The shakeout on that downgrade was a killer opportunity, and the stock is now back over $200. x.com 

Merck has downside risk even as Moderna soared 176% today, with Wall Street analysts seeing the stock potentially as low as $105 a share. x.com 

Moderna generates one-tenth of Bristol Myers Squibb's revenue, making their nearly equal valuations hard to justify. x.com 

Moderna's cancer-cure mystery and optimism are the conditions that drive big stock moves. Its theme is now hot to trade, alongside related stocks. CoreWeave's 2025 AI data-center IPO rode similar uncertainty about AI revenue while AI was hot; it now faces AI-spending worries. x.com 

Moderna looks likely to stay relatively stable above its gap-up price into next year, as big buyers return. A $6M sale of March 2027 $110 puts bets on exactly that, which seems logical. Yesterday's $30B was the second-largest dollar buy volume ever for the stock, after buy volumes had already re-emerged; January's buying, the largest since Q2 2024, came when the stock was above $100, versus about $50 now. x.com  x.com 

Moderna's approaching October 24 data release at a Madrid conference makes some pre-event profit-taking likely. After the release, the stock could be $400, $200 or $40; the outcome is unknown. x.com 

Moderna is extremely attractive because curing cancer is a big story, but more consolidation is likely first. The weekly chart shows a wide gap between price and the upper Bollinger Band, so volatility may need another week or two to ebb before the stock possibly starts moving higher. x.com